An immunohistochemical study has been carried out on fibre optic-biopsy specimens from patients with small cell lung cancer (SCLC) who had either died within 3 months, or who had survived more than 2 years. Long term survivors (LTS) were identified from completed clinical trials at major UK centres and were matched for age and sex within the trial with short term survivors (STS). The panel of immunohistochemical markers included those previously reported to be associated with prognosis, and reagents representative of both neuroendocrine and epithelial differentiation. A preliminary screen of 17 antibodies identified 11 as consistently reactive on paraffin-embedded material using streptavadin-biotin immunoperoxidase. Of 186 identified patients, 110 biopsy samples were retrieved. Of these, 70 gave sufficient material for analysis. All sections were scored by three observers without knowledge of the prognosis. The analysis failed to identify any antigen whose expression was correlated with prognosis. We conclude that, in fibre-optic biopsy specimens, immunohistochemical analysis does not add prognostic information in SCLC.
Small cell lung cancer SCLC is characterised by monomorphic, undifferentiated cells which typically show neuroendocrine (NE) properties such as high levels of dopa decarboxylase, creatinine kinase BB, neurone specific enolase (NSE) and bombesin, and the presence of neurosecretory granules. The tumour is usually disseminated at the time of diagnosis, shows a dramatic response to chemotherapy and radiation, but relapses quickly. Cure rates are extremely low with longterm disease free survival expected in only 3-5% of cases (Davis et al., 1984; Souhami & Law, 1990) . Although for many patients treatment is palliative, it might be possible to increase cure rate by intensifying treatment in patients identifiable as having better prognostic features at presentation. Clinical and biochemical information give considerable prognostic information (Rawson & Peto, 1990; Souhami et al., 1985) but studies relating histological subtype to prognosis have given conflicting results (Hansen et al 1978; Carney et al., 1981; Aisner et al., 1983; Vollmer et al., 1985; Hirsch et al., 1988) .
SCLC expresses antigens associated with both neuroendocrine and epithelial differentiation (Souhami et al., 1991) . Several groups have attempted to relate antigen expression in SCLC to clinical behaviour and prognosis (Allan et al., 1987; Hamid et al., 1987; Martignone et al., 1989; Ruckdeschel et al., 1991) . The results have been variable. Conversely, it has been suggested that NE features in lung adenocarcinoma are associated with a better response to chemotherapy (Skov et al., 1991) . We have recently undertaken an analysis of long term survival in SCLC treated in clinical trials in major centres in the UK (Souhami & Law, 1990) . These trials have given us the opportunity to examine diagnostic biopsy material immunohistochemically in an attempt to relate patterns of antigen expression to prognosis.
Materials and methods
Patients with SCLC surviving more than' 2 years were identified from trials forming part of a national study on longevity in SCLC (Souhami & Law, 1990 (Allan et al., 1987) , MBR1 (Martignone et al., 1989) , CEA (Ruckdeschel et al., 1991) , C terminal peptide of probombesin (Hamid et al., 1987) ], or in patients with other tumours [PC10 (Soomro & Whimster, 1990; Hall et al., 1990) , S100 (Fox et al., 1989) ].
This preliminary testing showed that some of the antibodies were suitable for the definitive study (AUA1, HMFG2, HNK1, LP34, PC1O, SWA20, MBR1, S100, NSE Chromogranin and CEA). The other reagents gave no specific staining on paraffin embedded sections of five cases NSE was demonstrated in less than 50% of cases overall and those which did stain showed similar results for both the LTS and the STS group (Figure 2) . Chromagranin expression was present in approximately 40% of cases and the distribution of positive cases showed no difference between the LTS and STS groups (Figure 2 ). Our previous report with HNK1 suggested that lack of staining may be associated with a poor prognosis (Sheppeard et al., 1987) , but the present results show no significant association of lack of staining with either the LTS or the STS group (Figure 2) . SWA20 expression on SCLC was variable (Figure 3 ) with no relationship to prognostic category. In a small number of cases in both study groups occasional S100 positive dendritic cells were seen (Table III) . Results with PC10, an antibody to PCNA (proliferating cell nuclear antigen), were uninterpretable in most of our cases because of the nuclear crush artefact commonly present in fibre-optic biopsies of SCLC.
Discussion
There have been many attempts to relate biological characteristics of SCLC to prognosis. Cytomorphological characteristics of the tumour have been examined (Burdon et al., 1979; Carney et al., 1981; Vollmer et al., 1985; Hirsch et al., 1988) but the evidence that the tumours with a large cell component have a worse prognosis is not convincing. Serum markers such as NSE (Harding et al., 1990 ) are related to prognosis but appear to be indicators of mass of disease rather than independent predictors of outcome. The same has been suggested for CEA (Sculier et al., 1985; Laberge et al., 1987) In the present study we have tried to avoid some of these difficulties. The groups of patients have been taken at the extremes of prognosis (survival < 3 months or > 2 years) since, if no difference is detectable, it seems unlikely that one will be detected from a population with a wide distribution of prognosis. Each short survivor was the next age and sex matched case entered into the same treatment trial as the long survivor. In this way we have attempted to minimise treatment effects. The patients whose specimens were adequate appeared to be representative of the larger group as judged by age and sex. Finally, the slides were read and scored by three independent observers without knowledge of outcome.
Antibodies used in this study were selected to include markers previously reported as being related to prognosis in SCLC and reagents recognising neuroendocrine and epithelial antigens previously identified on SCLC. AUA1 binds to a 4OKd membrane glycoprotein (Spurr et al., 1986; Strnad et al., 1989) , designated as Cluster 2 in the Lung Cancer Antibody Workshops (Souhami et al., 1991) . The antigen appears to be a homologue of the cell adhesion protein nidogen (Simon et al., 1990) . LP34 recognises cytokeratins 5, 8, 16, 10 and 14, which are expressed by epithelia showing squamous and glandular differentiation (Lane & Alexander, 1990) .
HMFG2 recognises an epitope on a large 180Kd epithelial mucin which is expressed on normal and lactating breast epithelium and breast carcinoma cells. The lack of expression of this antigen in over fifty per cent of our cases is of interest since it has been a target antigen for immunolocalisation (Epenetos et al., 1982) . MBR1, like HMFG2, was initially raised and studied in the context of breast carcinoma.
CEA is one of the most widely studied tumour-associated antigens which has recently been shown to belong to the immunoglobulin superfamily of cell adhesion molecules (Pignatelli et al., 1990) . It is strongly expressed in a wide range of adenocarcinomas (Sheahan et al., 1990) , and in just over half of small cell lung cancers (Bepler et al., 1989) . The gamma dimer of NSE, a glycolytic enzyme found in the brain, has been widely used as a marker of neuroendocrine differentiation in tumours (Sheppard et al., 1984) . Chromogranin A is a soluble protein in dense core granules and has been demonstrated immunohistochemically in approxim ately 50% of SCLC in most reported series (Wilson & Lloyd, 1984) . HNK1 has been shown to be expressed on SCLC, carcinoids, some adenocarcinomas, natural killer cells and neural tissues, and belongs to the CD54 category of leucocyte differentiation antigens which is an epitope of NCAM (Kruse et al., 1984) . SWA20 (designated as Cluster 5) is an antibody which shows a mixed neural and epithelial reactivity (Waibel et al., 1988) . S1OO is a brain protein which has a wide tissue distribution including Langerhans cells. Several studies on the presence and extent of these cells within other malignant tumours, and the relationship of their distribution to prognosis, have been carried out (Fox et al., 1989) .
The results of this study do not confirm previous findings (Allan et al., 1987; Hamid et al., 1987; Martignone et al., 1989 , Ruckdeschel et al., 1991 that the use of immunohistochemistry can identify patients with a good or bad prognosis with SCLC. This negative result must itself be interpreted cautiously. Firstly we examined mainly fibre-optic bronchoscopy specimens which, of course, may not represent the whole tumour. Nevertheless these are the specimens which the pathologist receives in the vast majority of cases and on which the clinician makes a judgement about treatment. Prognostic indicators based on surgically resected SCLC will be of very limited value. Secondly the panel clearly does not represent all possible antigens on SCLC. The neural cell adhesion molecule (NCAM) designated as Cluster 1 in the Lung Cancer Workshops (Souhami et al., 1991 ) is a marker indicative of the neuroendocrine status of the tumour. Unfortunately it is lost in formalin fixation unless zinc sulphate is added (Tome et al., 1990 ) and so could not be used in this study. Nevertheless Chromogranin, HNK1 and NSE are neuroendocrine markers and showed no relationship to prognosis. This data from the present study cannot however be regarded as conclusive on this point and further, prospective, studies are needed.
For the present it does not appear that any immunohistochemical staining can be recommended as a valuable addition to the routine diagnosis of SCLC, or to the other clinical and investigational findings on which a judgement about prognosis and treatment is made.
